ELISpot and FluoroSpot Assay Market Expands with Technological Innovations in T-cell and B-cell Based Diagnostic and Research Kits

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ELISpot and FluoroSpot Assay Market- (By Product (Assay Kits (Assay Kits by Technique(ELISpot Assay Kits, FluroSpot Assay Kits), Assay Kits by Utility (Diagnostic Kits, Research Kits), Assay Kits by Analyte (T-cell-based kits, B-cell-based kits, Other analytic kits), Analyzers, Ancillary products), By Application (Diagnostic Applications (Infectious Diseases, Transplants), Research Applications (Vaccine Development, Clinical Trials, Cancer Research)), By End-User (Hospitals & Clinical Labs, Research Institutes, Biopharmaceutical Companies and CROs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global ELISpot and FluoroSpot Assay Market is valued at US$ 276.18 Mn in 2022, and it is expected to reach US$ 512.39 Mn by 2031, with a CAGR of 7.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2000

The growing prevalence of chronic illnesses, including cancer and autoimmune disorders, is a significant driver of the Enzyme-Linked Immunospot (ELISPOT) and Fluorospot assay market. These diagnostic assays are essential for the early detection of diseases, tracking disease progression, and assessing the efficacy of therapeutic interventions. However, it is worth noting that the National Cancer Institute has recommended against utilizing ELISPOT assays for monitoring immune responses to cancer antigens in clinical therapeutic trials. In parallel, the increasing incidence of infectious diseases such as Human Immunodeficiency Virus (HIV) and tuberculosis is contributing to the rising demand for these assays. ELISPOT and Fluorospot tests offer critical insights into disease-specific biomarkers and immune responses to infectious agents, underscoring their importance in both clinical research and healthcare delivery.

List of Prominent Players in the ELISpot and FluoroSpot Assay Market:
• Oxford Immunotec (UK)
• Cellular Technology Limited (US)
• Mabtech (Sweden)
• Becton Dickinson and Company (US)
• Abcam plc. (UK)
• Bio-Techne. (US)
• Mikrogen Diagnostik (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherlands)
• Medix Biochemica (Finland)
• Merck KGaA (Germany)
• Bio-Sys GmbH (Germany)
• Anogen-Yes Biotech Laboratories Ltd (Canada)
• Abnova Corporation (Taiwan)
• Biorbyt Ltd (UK),
• Tokyo Chemical Industry Co., Ltd. (Japan),
• MP BIOMEDICALS. (US),
• BOC Sciences. (US),
• ZenBio, Inc (US)
• Jackson ImmunoResearch Inc (US),
• Krishgen Biosystems. (India)
• NATIONAL ANALYTICAL CORPORATION (India),
• STEMCELL Technologies Inc. (Canada),
• SERVA Electrophoresis GmbH (Germany),
• IST Scitific LTD (England).

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
Manufacturers are increasingly pursuing strategic acquisitions, partnerships, and collaborations with regional and local companies to address the rising demand for ELISpot and FluoroSpot assay diagnostics in emerging markets. For example, in February 2022, Siemens Healthineers (Germany) entered into a partnership with UNICEF (United States) to strengthen healthcare infrastructure in Sub-Saharan Africa by enhancing access to diagnostic services and treatment. Additionally, regulatory frameworks in the Asia Pacific region tend to be more flexible and conducive to business growth compared to the more stringent regulations in North America and Europe. As competition intensifies in mature markets, manufacturers of ELISpot and FluoroSpot assays are increasingly turning their attention to growth opportunities in Asia Pacific and Latin America.

Challenges:
Intracellular cytokine staining (ICS) followed by flow cytometry remains the most widely utilized method for assessing cytokine co-expression cells, presenting a significant competitive hurdle for FluoroSpot assays. While FluoroSpot offers superior sensitivity, ICS is often favored for its robust performance, particularly in accurately identifying fluorescent signals-an area where FluoroSpot assays face challenges due to potential overlap in the detection wavelengths of various fluorescent dyes. In response, industry players are advancing their detection technologies. For instance, Mabtech AB has developed the IRIS analyzer, which employs RawSpot technology to enhance the precision of spot detection.

Regional Trends:
North America is projected to maintain a dominant position in the ELISpot and FluoroSpot assay market throughout the forecast period. This growth is primarily driven by the high incidence of cancer and infectious diseases in the region. According to the American Cancer Society's Cancer Statistics 2022, approximately 1.92 million new cancer cases were anticipated in the United States in 2022, including breast cancer, leukemia, and lymphoma. Moreover, a study by the American Academy of Pediatrics published in March 2022 reported that over one million individuals in the United States are living with chronic hepatitis B infections, which can progress to severe conditions such as liver cancer. The increasing disease burden is expected to elevate demand for vaccinations and fuel the adoption of ELISpot assays, which are highly effective in infectious disease research.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2000

Recent Developments:
• In Mar 2023, The T-Cell Select reagent kit from Oxford Immunotec, which is designed for in vitro diagnostic (IVD) use by accredited laboratories using the T-SPOT.TB test workflow, has received approval from the U.S. Food and Drug Administration (FDA) for the use of two additional cell isolation tools.
• In Mar 2022, Medix Biochemica launched a new brand to show how its recent acquisitions have made its services more exciting and how committed it is to the in vitro diagnostics (IVD) business. Medix Biochemica became the best IVD raw materials seller because of how quickly it grew.

Segmentation of ELISpot and FluoroSpot Assay Market-
By Product-
• Assay Kits
o Assay Kits by Technique
 ELISpot Assay Kits
 FluroSpot Assay Kits
o Assay Kits by Utility
 Diagnostic Kits
 Research Kits
o Assay Kits by Analyte
 T-cell-based kits
 B-cell-based kits
 Other analytic kits
• Analyzers
• Ancillary products
By Application-
• Diagnostic Applications
o Infectious Diseases
o Transplants
• Research Applications
o Vaccine Development
o Clinical Trials
o Cancer Research
By End-User-
• Hospitals & Clinical Labs
• Research Institutes
• Biopharmaceutical Companies and CROs
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/elispot-and-fluorospot-assay-market/2000

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.